コレステロール低下薬市場：疾患タイプ、薬剤クラス別、流通チャネル別-2025～2030年の世界予測

コレステロール低下薬市場は、2023年に220億米ドルと評価され、2024年には238億米ドルに達すると予測され、CAGR 8.30%で成長し、2030年には384億5,000万米ドルに達すると予測されています。

コレステロール低下薬市場は、医薬品業界の重要なセグメントであり、心血管疾患を予防するために、主にLDLコレステロールを対象として血中のコレステロール値を低下させるように設計された薬剤に焦点を当てています。このような薬剤の必要性は、食生活の乱れ、運動不足、高齢化などのライフスタイル要因によるコレステロール関連疾患の世界の増加によって強調されています。その用途は、リスクのある人々に対する予防治療から、すでに心血管疾患を患っている人々に対する介入まで幅広く、エンドユーザーには病院、クリニック、慢性疾患を管理する個人などが含まれます。この市場の成長は主に、高コレステロール血症の有病率の増加、高齢者の拡大、心臓の健康に対する意識の高まりに影響されます。

しかし、ブランド薬の高コスト、潜在的な副作用、服薬アドヒアランスの課題などの制約が市場拡大の妨げとなる可能性があります。さらに、代替療法や生活習慣別の介入の人気が高まっていることも、競争上の課題となっています。こうした障害にもかかわらず、潜在的なビジネス機会は、新規の生物製剤やバイオシミラーの開発、個別化医療のアプローチ、医療アクセスが改善しつつある新興国市場の拡大にあります。このような機会を捉えるために、製薬会社は次世代コレステロール低下薬の研究開発に投資し、データ分析を活用して個別化治療計画を策定することをお勧めします。

イノベーションは、複数の心血管危険因子に対処する併用療法や、患者のモニタリングとアドヒアランスを支援するデジタルヘルス技術に焦点を当てることができます。遺伝子治療や栄養補助食品の調査も、画期的な治療法として有望です。市場の競争は激化しているが、アンメット・メディカル・ニーズと技術の進歩に後押しされ、潜在的な可能性に満ちています。バイオテクノロジー企業と研究機関の提携は創薬プロセスをさらに強化する可能性があり、医療プロバイダーとの戦略的提携は患者関与と市場浸透を改善する可能性があります。

市場力学：急速に進化するコレステロール低下薬市場における主要市場洞察の解明

コレステロール低下薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のLDLコレステロールの負担増
  • コレステロールを合併する高齢者の増加
  • 喫煙と飲酒の増加が高コレステロールのリスクを高める
• 市場抑制要因
  • 横紋筋融解症を引き起こすスタチンの重篤な副作用
• 市場機会
  • 医療インフラの強化に向けた政府の投資
  • PCSK9阻害剤の登場など、薬剤製剤の開発と新しい治療法の出現
• 市場課題
  • 主要ブランドのジェネリック医薬品の入手可能性と厳しい承認プロセス

ポーターのファイブフォース：コレステロール低下薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：コレステロール低下薬市場における外部からの影響の把握

外部マクロ環境要因は、コレステロール低下薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：コレステロール低下薬市場における競合情勢の把握

コレステロール低下薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックスコレステロール低下薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、コレステロール低下薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：コレステロール低下薬市場における成功への道筋を描く

コレステロール低下薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でLDLコレステロールの負担が増加
    • コレステロール合併症を持つ高齢者の増加
    • 喫煙とアルコール摂取の増加は高コレステロールのリスクを高める
  • 抑制要因
    • スタチンの重篤な副作用による横紋筋融解症
  • 機会
    • 医療インフラ強化に向けた政府投資
    • 薬剤配合の開発とPCSK9阻害剤の出現などの新しい治療法の出現
  • 課題
    • 主要ブランドのジェネリック医薬品の入手可能性と厳格な承認プロセス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 コレステロール低下薬市場：疾患タイプ別

• イントロダクション
• 心血管疾患
• 高コレステロール血症
• 高脂血症

第7章 コレステロール低下薬市場：薬剤タイプ別

• イントロダクション
• コレステロール吸収阻害剤
• フィブラート
• 固定用量の組み合わせ
• イオン交換樹脂
• 新しいコレステロール低下薬
• PCSK9阻害剤
• スタチン

第8章 コレステロール低下薬市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのコレステロール低下薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のコレステロール低下薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのコレステロール低下薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Anant Pharmaceuticals Pvt. Ltd.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Covis Pharma GmbH
• Daiichi Sankyo Co., Ltd.
• Dr. Reddy's Laboratories Ltd.
• Kowa Company, Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. CHOLESTEROL LOWERING DRUG MARKET RESEARCH PROCESS
• FIGURE 2. CHOLESTEROL LOWERING DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHOLESTEROL LOWERING DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHOLESTEROL LOWERING DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CHOLESTEROL ABSORPTION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIBRATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ION EXCHANGE RESINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY NOVEL CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 33. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 35. CANADA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 50. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 52. CHINA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 53. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 55. INDIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 105. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 107. ITALY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 117. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 119. POLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 120. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 122. QATAR CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY CLASS OF DRUG, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM CHOLESTEROL LOWERING DRUG MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 150. CHOLESTEROL LOWERING DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. CHOLESTEROL LOWERING DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Cholesterol Lowering Drug Market was valued at USD 22.00 billion in 2023, expected to reach USD 23.80 billion in 2024, and is projected to grow at a CAGR of 8.30%, to USD 38.45 billion by 2030.

The market for cholesterol-lowering drugs is a vital segment of the pharmaceutical industry, focusing on medications designed to reduce cholesterol levels in the blood, primarily targeting LDL cholesterol, to prevent cardiovascular diseases. The necessity for such drugs is underscored by the global rise in cholesterol-related conditions, driven by lifestyle factors such as poor diet, lack of exercise, and an aging population. Their application ranges from preventive treatments for at-risk individuals to interventions for those with existing cardiovascular issues, with end-users including hospitals, clinics, and individuals managing chronic conditions. Growth in this market is primarily influenced by the increasing prevalence of hypercholesterolemia, an expanding geriatric population, and heightened awareness of heart health.

However, limitations such as high costs of branded medications, potential side effects, and medication adherence challenges can hinder market expansion. Moreover, the growing popularity of alternative therapies and lifestyle-based interventions presents a competitive challenge. Despite these obstacles, potential opportunities lie in the development of novel biologics and biosimilars, personalized medicine approaches, and expanding markets in emerging economies where healthcare access is improving. To seize these opportunities, pharmaceutical companies are advised to invest in R&D for next-generation cholesterol-lowering agents and leverage data analytics to develop personalized treatment plans.

Innovation could focus on combination therapies that address multiple cardiovascular risk factors, as well as digital health technologies that assist in patient monitoring and adherence. Research into gene therapy and nutraceuticals also offers promising avenues for breakthrough treatments. The nature of the market is increasingly competitive yet ripe with potential, driven by unmet medical needs and technological advancements. Collaborations between biotech firms and research institutions could further enhance drug discovery processes, while strategic alliances with healthcare providers could improve patient engagement and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cholesterol Lowering Drug Market

The Cholesterol Lowering Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising burden of LDL cholesterol across the globe
  • Growing geriatric population with cholesterol complications
  • Increase in smoking and alcohol consumption escalate the risk of high cholesterol
• Market Restraints
  • Severe side effects of statins causing rhabdomyolysis
• Market Opportunities
  • Government investment toward the strengthening healthcare infrastructure
  • Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
• Market Challenges
  • Availability of generic drugs of leading brands and stringent approvals process

Porter's Five Forces: A Strategic Tool for Navigating the Cholesterol Lowering Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cholesterol Lowering Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cholesterol Lowering Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cholesterol Lowering Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cholesterol Lowering Drug Market

A detailed market share analysis in the Cholesterol Lowering Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cholesterol Lowering Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cholesterol Lowering Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cholesterol Lowering Drug Market

A strategic analysis of the Cholesterol Lowering Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cholesterol Lowering Drug Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Covis Pharma GmbH, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Kowa Company, Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cholesterol Lowering Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia.
• Based on Class of Drug, market is studied across Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins.
• Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising burden of LDL cholesterol across the globe
    • 5.1.1.2. Growing geriatric population with cholesterol complications
    • 5.1.1.3. Increase in smoking and alcohol consumption escalate the risk of high cholesterol
  • 5.1.2. Restraints
    • 5.1.2.1. Severe side effects of statins causing rhabdomyolysis
  • 5.1.3. Opportunities
    • 5.1.3.1. Government investment toward the strengthening healthcare infrastructure
    • 5.1.3.2. Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of generic drugs of leading brands and stringent approvals process
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cholesterol Lowering Drug Market, by Disease Type

• 6.1. Introduction
• 6.2. Cardiovascular Diseases
• 6.3. Hypercholesterolemia
• 6.4. Hyperlipidemia

7. Cholesterol Lowering Drug Market, by Class of Drug

• 7.1. Introduction
• 7.2. Cholesterol Absorption Inhibitors
• 7.3. Fibrates
• 7.4. Fixed-Dose Combinations
• 7.5. Ion Exchange Resins
• 7.6. Novel Cholesterol-Lowering Drugs
• 7.7. PCSK9 Inhibitors
• 7.8. Statins

8. Cholesterol Lowering Drug Market, by Distribution Channels

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Cholesterol Lowering Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cholesterol Lowering Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cholesterol Lowering Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Anant Pharmaceuticals Pvt. Ltd.
• 3. AstraZeneca PLC
• 4. Bristol-Myers Squibb Company
• 5. Covis Pharma GmbH
• 6. Daiichi Sankyo Co., Ltd.
• 7. Dr. Reddy's Laboratories Ltd.
• 8. Kowa Company, Ltd.
• 9. Merck & Co., Inc.
• 10. Novartis AG
• 11. Pfizer Inc.
• 12. Sanofi
• 13. Sun Pharmaceutical Industries Ltd.
• 14. Teva Pharmaceutical Industries Ltd.
• 15. Viatris Inc.